For Lilly’s Donanemab, US FDA Commissioner Is Already Thinking About Post-Market Questions

 
• By Sarah Karlin-Smith
rising sun Alzheimer's
Lilly's donanemab data prompted Califf to discuss the dawning of a new era in Alzheimer's treatments. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

More from US FDA

More from Agency Leadership